Heteroaromatic compounds and their use as dopamine D1 ligands

US9688698B2 · kind B2 · utility

Assignee

• PFIZER INC. · US

Inventors

• David Lawrence Firman Gray · Groton, US
• Lei Zhang · Beijing, CN
• Jennifer Elizabeth Davoren · Cambridge, US
• Amy Beth Dounay · Colorado Springs, US
• Ivan Viktorovich Efremov · Sharon, US
• Scot Richard Mente · Arlington, US
• Chakrapani Subramanyam · South Glastonbury, US

Key dates

• Filing date: Apr 23, 2015
• Grant date: Jun 27, 2017
• Expiry date: Jun 6, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides, in part, compounds of Formula I:and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.